128 related articles for article (PubMed ID: 24165911)
1. Prevention: Rosuvastatin can prevent contrast-induced AKI.
Roberts A
Nat Rev Cardiol; 2013 Dec; 10(12):679. PubMed ID: 24165911
[No Abstract] [Full Text] [Related]
2. Do statins reduce the risk of contrast-induced acute kidney injury in patients undergoing coronary angiography or percutaneous coronary interventions?
Alpert MA
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):80-2. PubMed ID: 24076280
[No Abstract] [Full Text] [Related]
3. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Han Y; Zhu G; Han L; Hou F; Huang W; Liu H; Gan J; Jiang T; Li X; Wang W; Ding S; Jia S; Shen W; Wang D; Sun L; Qiu J; Wang X; Li Y; Deng J; Li J; Xu K; Xu B; Mehran R; Huo Y
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):62-70. PubMed ID: 24076297
[TBL] [Abstract][Full Text] [Related]
4. ACP Journal Club. Early high-dose rosuvastatin prevented contrast-induced acute kidney injury in non-ST-elevation ACS.
Molnar AO; Garg AX
Ann Intern Med; 2014 May; 160(10):JC9. PubMed ID: 24842443
[No Abstract] [Full Text] [Related]
5. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
Leoncini M; Toso A; Maioli M; Tropeano F; Villani S; Bellandi F
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):71-9. PubMed ID: 24076283
[TBL] [Abstract][Full Text] [Related]
6. Intravenous hydration (with or without rosuvastatin) should remain the cornerstone of the prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Cecere N; Jadoul M; Labriola L
J Am Coll Cardiol; 2014 Jul; 64(3):332. PubMed ID: 25034074
[No Abstract] [Full Text] [Related]
7. Reply: Intravenous hydration (with or without rosuvastatin) should remain the cornerstone of the prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Han Y
J Am Coll Cardiol; 2014 Jul; 64(3):332-3. PubMed ID: 25034073
[No Abstract] [Full Text] [Related]
8. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
[TBL] [Abstract][Full Text] [Related]
9. Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography.
Abaci O; Arat Ozkan A; Kocas C; Cetinkal G; Sukru Karaca O; Baydar O; Kaya A; Gurmen T
Am J Cardiol; 2015 Apr; 115(7):867-71. PubMed ID: 25670636
[TBL] [Abstract][Full Text] [Related]
10. Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.
Leoncini M; Toso A; Maioli M; Tropeano F; Badia T; Villani S; Bellandi F
Am Heart J; 2014 Nov; 168(5):792-7. PubMed ID: 25440809
[TBL] [Abstract][Full Text] [Related]
11. Statins for the prevention of contrast-induced acute kidney injury.
Ball T; McCullough PA
Nephron Clin Pract; 2014; 127(1-4):165-71. PubMed ID: 25343843
[TBL] [Abstract][Full Text] [Related]
12. [The PRATO-ACS study].
Marenzi G; Briguori C
G Ital Cardiol (Rome); 2013 Dec; 14(12):803-8. PubMed ID: 24336595
[No Abstract] [Full Text] [Related]
13. Impact of high-dose statin pre-treatment and contrast-induced acute kidney injury on follow-up events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Patti G; Leoncini M; Toso A; Maioli M; Grieco D; Colonna G; Bellandi F; Di Sciascio G
Int J Cardiol; 2014 Jun; 174(2):440-1. PubMed ID: 24767765
[No Abstract] [Full Text] [Related]
14. Short-term rosuvastatin treatment for the prevention of contrast-induced acute kidney injury in patients receiving moderate or high volumes of contrast media: a sub-analysis of the TRACK-D study.
Zhang J; Li Y; Tao GZ; Chen YD; Hu TH; Cao XB; Jing QM; Wang XZ; Ma YY; Wang G; Liu HW; Wang B; Xu K; Li J; Deng J; Han YL
Chin Med J (Engl); 2015 Mar; 128(6):784-9. PubMed ID: 25758273
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury After Cardiac Catheterization: A Meta-Analysis of Randomized Controlled Trials.
Yang Y; Wu YX; Hu YZ
Medicine (Baltimore); 2015 Jul; 94(30):e1226. PubMed ID: 26222855
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
Kaya A; Kurt M; Tanboğa IH; Işik T; Ekinci M; Aksakal E; Kaya Y; Topçu S; Sevimli S
Acta Cardiol; 2013 Oct; 68(5):489-94. PubMed ID: 24283110
[TBL] [Abstract][Full Text] [Related]
17. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
Lablanche JM; Danchin N; Farnier M; Tedgui A; Vicaut E; Alonso J; Crean P; Leone A; Morais J; Santini M; Licour M; Farah M; Tardif JC
Arch Cardiovasc Dis; 2008 Jun; 101(6):399-406. PubMed ID: 18809153
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.
Lablanche JM; Leone A; Merkely B; Morais J; Alonso J; Santini M; Eha J; Demil N; Licour M; Tardif JC;
Arch Cardiovasc Dis; 2010 Mar; 103(3):160-9. PubMed ID: 20417447
[TBL] [Abstract][Full Text] [Related]
19. The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome.
Sexton TR; Wallace EL; Macaulay TE; Charnigo RJ; Evangelista V; Campbell CL; Bailey AL; Smyth SS
J Am Coll Cardiol; 2015 Jan; 65(3):306-7. PubMed ID: 25614429
[No Abstract] [Full Text] [Related]
20. Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation).
Poyet R; Cuisset T; Frere C; Quilici J; Gaborit B; Moro PJ; Camoin L; Morange PE; Bonnet JL; Alessi MC
Thromb Res; 2010 Nov; 126(5):e397-9. PubMed ID: 20825983
[No Abstract] [Full Text] [Related]
[Next] [New Search]
